JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Add like
Add dislike
Add to saved papers

Hepatitis C virus-associated glomerulonephritis.

Hepatitis C virus (HCV) infection remains a major global health burden. In addition to liver-related morbidity and mortality due to hepatic decompensation and development of hepatocellular carcinoma, extrahepatic manifestations of hepatitis C are frequent. Type I membranoproliferative glomerulonephritis associated with type II cryoglobulinemia is the most frequent association. The pathogenesis of the renal lesions is related to glomerular deposition of immune complexes. International guidelines recommend that patients with HCV-related glomerulopathies should be treated with antiviral therapy in the form of standard or pegylated interferon-α and ribavirin. The recent development of direct-acting antiviral agents that inhibit the various steps of the viral life cycle represents a major milestone for the treatment of chronic HCV infection. Initial reports suggest that they are safe in ESRD subjects. However, data is lacking on their efficacy and safety in HCV-related glomerulonephritis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app